Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-28
2010-06-01
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S304700, C548S146000, C548S215000, C548S240000, C548S131000, C548S207000, C540S215000, C514S398000, C514S399000, C514S256000, C514S364000, C514S277000, C514S406000, C544S224000, C544S295000
Reexamination Certificate
active
07728025
ABSTRACT:
A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive for obesity are provided.A glucokinase activator characterized by containing a 2-heteroaryl-substituted benzimidazole derivative of a general formula (I-0) or its pharmaceutically-acceptable salt:[in the formula, X represents a carbon atom or a nitrogen atom;X1, X2, X3and X4each independently represent a carbon atom or a nitrogen atom; the ring A represents a 5- or 6-membered nitrogen-containing aromatic hetero ring of a formula (II):(in the formula, X represents a carbon atom or a nitrogen atom); R1represents an aryl, etc.; R2represents a hydroxy, etc.; R3represents a —C1-6alkyl, etc.; R4represents a —C1-6alkyl, etc.; X5represents —O—, etc.; a indicates an integer of 1, 2 or 3; q indicates an integer of from 0 to 2; m indicates an integer of from 0 to 2].
REFERENCES:
patent: 3370957 (1968-02-01), Wagner et al.
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 6040449 (2000-03-01), Tsuchiya et al.
patent: 6239152 (2001-05-01), Gordeev et al.
patent: 7064215 (2006-06-01), Renhowe et al.
patent: 2005/0272740 (2005-12-01), Dorsch et al.
patent: 2006/0167053 (2006-07-01), Iino et al.
patent: 2006/0258701 (2006-11-01), Mitsuya et al.
patent: 2007/0088071 (2007-04-01), Kim et al.
patent: 2008/0085926 (2008-04-01), Stelmach et al.
patent: 2008/0125429 (2008-05-01), Hashimoto et al.
patent: 1237731 (1964-05-01), None
patent: 0 726 260 (1996-08-01), None
patent: 2000 26430 (2000-01-01), None
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, pp. 205-213.
Grupe, A. et al., “Transgenic Knockouts Reveal a Critical Requirement for Pancreatic B Cell Glucokinase in Maintaining Glucose Homeostasis”, Cell, vol. 83, pp. 69-78, 1995.
Mitsunobu, O., “The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products”, Synthesis, vol. 1, pp. 1-28, 1981.
Tani, Junichi, et al., “Studies on biologically Active Halogenated Compounds IV Synthesis and Antibaterial Activity of Fluorinated Quinoline Derivatives”, Chemical and Parmaceutical Bulletin, vol. 30, pp. 3530-3543, 1982.
Tasneem, et al., “Ammonium Nickel Sulphate Mediated Nitration of Aromatic Compounds with Nitric Acid”, Synthetic Communications, vol. 31 (7), pp. 1123-1127, 2001.
Fonseca, T. et al., “A short synthesis of phenanthrol[2,3-d]imidazoles from dehydroabietic acid. Application of the methodology as a convenient route to benzimidazoles” Tetrahedron, vol. 57, pp. 1793-1799, 2001.
Singh, M.P. et al., “Synthetic Utility of Catalytic Fe(III)/Fe(II) Redox Cycling Towards Fused Heterocycles: A Facile Access to Substituted Benzimidazole, Bis-benzimidazole and Imidazopyridine Derivatives” Synthesis, vol. 10, pp. 1380-1390, 2000.
Singh, S.P. et al., “Reaction of 2-hydrazinobenzhnidazole with B-diketones: A structural reinvestigation” Indian Journal of Chemistry, vol. 32, pp. 262-265, 1993.
Ferre, T. et al., “Correction of diabetic alterations by glucokinase”, Proc. Natl. Acad. Sci, vol. 93, pp. 7225-7230, 1996.
Glaser, B. et al., “Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation” The new England Journal of Medicine, vol. 338, pp. 226-230, 1998.
Dolle, F. et al., “Synthesis and Nicotinic Acetylcholine Receptor in Vivo Binding Properties of 2-Fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: A New Positron Emission Tomography Ligand for Nicotinic Receptors” J. Med. Chem, vol. 42, pp. 2251-2259, 1999.
Sitzmann, M. E. et al., “Fluronitroanilines Reaction Control via Hydrogen Bonding”, J. Org. Chem, vol. 43, (6), pp. 1241-1243, 1978.
Vionnet, N. et al., “Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus” Nature, vol. 356, pp. 721-722, 1992.
Arakawa Keisuke
Ishikawa Makoto
Nagae Yoshikazu
Nakashima Hiroshi
Nishimura Teruyuki
Banyu Pharmaceutical Co. Ltd.
Billups Richard C.
Rodriguez-Garcia Valerie
Saeed Kamal A
Todaro John C.
LandOfFree
2-heteroaryl-substituted benzimidazole derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-heteroaryl-substituted benzimidazole derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-heteroaryl-substituted benzimidazole derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248229